Wednesday, November 9, 2022 / 3:00 PM - 4:00 PM EST
Title: Human Dendritic Cells as Novel Cellular Therapeutics
Speaker:
Yen-Michael Sheng Hsu, MD, PhD
Associate Professor of Medicine
Director of Immunologic Monitoring and Cellular Products Laboratory
Director of UPMC Adult Hematopoietic Stem Cell Laboratory
Co-Leader, UPMC Hillman Cancer Center Cellular Therapeutic Program
UPMC Hillman Cancer Center
University of Pittsburgh School of Medicine
Speaker Bio:
Dr. Yen-Michael S. Hsu received a Bachelor of Arts degree in Molecular and Cell Biology with honors from UC Berkeley, followed by the completion of MD/PhD (Immunology) training at University of Texas Health Science Center and MD Anderson Cancer Center, Clinical Pathology residency training at Washington University School of Medicine, and the Transfusion Medicine/Blood Banking clinical fellowship training at UCSF Medical Center. Dr. Hsu is a Pennsylvania and New York state licensed physician and a double board-certified pathologist in Clinical Pathology and Transfusion Medicine/Blood Banking.
Prior to joining University of Pittsburgh Medical Center Hillman Cancer Center (UPMC HCC), Dr. Hsu was an associate professor in the Department of Pathology at NewYork Presbyterian Hospital/Weill Cornell Medical Center. Administratively he served as the Chief of Cellular Therapy and the Inaugural medical/laboratory director of a cGMP cellular therapy laboratory (LACE, Laboratory for Advanced Cellular Engineering), which he established in 2017. In 2021, Dr. Hsu was recruited to UPMC HCC as an associate professor of hematology and oncology in the Department of Medicine at the University of Pittsburgh School of Medicine. Additionally, he serves as the medical and laboratory director of the Immunologic Monitoring and Cellular Production Laboratory (IMCPL), which is the centralized FACT/CAP accredited cGMP cellular therapy manufacturing facility supporting over 10 different cellular and biologic IND manufacturing and processing, handling all FDA approved CAR-T products, and directing laboratory supports for 35+ clinical trials at UPMC HCC. Administratively, Dr. Hsu is the member of the UPMC HCC Cancer Cancer Immunology and Immunotherapy Program (CIIP) and the co-leader of the UPMC HCC Cellular Therapeutic Program. Additionally, Dr. Hsu serves as the medical/laboratory director of the UPMC HCC adult HSC laboratory under FACT/CAP accreditations that supports all clinical stem cell transplantations.
Dr. Hsu is an established physician scientist who serves as a principal investigator and co-investigator in multiple intramurally and extramurally funded cellular therapy clinical studies. Externally, Dr. Hsu is a member of several professional societies in the field of pathology and cellular therapy. He serves in various leadership positions, such as subcommittee chairs, laboratory inspector/assessor, in AABB, CAP and FACT, which the main US-based international accreditation agencies for cellular therapy and laboratory medicine practices.
Dr. Hsu is an enthusiastic teaching faculty who had served as an Assistant Director of Pathology Residency Program at Weill Cornell Medicine, Course Director in Transfusion Medicine, Course Director in Cellular Therapy, invited lecturer at New York Blood Center, and invited teaching faculty at the Weill Cornell Medical School and University of Pittsburgh. Dr. Hsu has been active to give invited research presentations nationally and internationally.
Dr. Hsu receives many accolades and merit-based recognitions from professional societies and home institutions. In 2021, Dr. Hsu has been named as a Hillman Fellow for Innovative Cancer Research towards independent and collaborative research.
Abstract:
Human dendritic cells (hDCs) have been known as the professional antigen presenting cells (APC) since the early 1970's. The fundamental property of this innate immune cells to elicit critical immune responses in adaptive immunity confers the host anti-microbial ability and survival. In the past four decades, a myriad of human hDC subpopulations have been identified and characterized. In addition to the well-known function of augmenting anti-microbial immunity, hDCs have been known to modulate host immunity as well as have anti-cancer property. In this presentation, a single-institutional experience in hDC manufacturing as an FDA investigational new drug (IND) would be described and its application in anti-viral therapy, solid organ transplant rejection mitigation therapy, and anti-tumor therapy would be discussed.
Objectives:
1. Understand the basic function of human dendritic cells (hDCs)
2. Learn the basic manufacturing and testing of hDC products
3. Exposure to various clinical applications of hDC in clinical trials
Disclosures:
Avalon GloboCare Corp., Research Funding and Scientific/Clinical Advisory Board Member
Pricing:
- Members: FREE (Registration is required.)
- Non-Members: $45 per session & $130 entire series
- Institutions: $75 per session & $200 entire series
To receive member pricing, be sure to sign in.
